LAG-3/PD-1 Blockade Aims to Tackle Immunotherapy Resistance Up Front in Nonsquamous NSCLC

The phase 3 RELATIVITY-1093 trial is investigating whether adding LAG-3 blockade to frontline chemoimmunotherapy improves survival compared with the pembrolizumab-based standard in patients with PD-L1-positive nonsquamous NSCLC. The approach builds on positive phase 2 data suggesting enhanced response rates and progression-free survival without increased severe toxicity.

This Wire brief sits within Fusion42's coverage of Biotech.